Preliminary results of interstitial motexafin lutetium-mediated PDT for prostate cancer
Preliminary results of interstitial motexafin lutetium-mediated PDT for prostate cancer
复制标题
DOI：
10.1002/lsm.20341
复制
发表时间：
2006-06-01
影响因子：
2.4
通讯作者：
Hahn, S. M.
中科院分区：
文献类型：
--
作者：
Du, K. L.;Mick, R.;Hahn, S. M.
背景和目的：间质性光动力疗法（PDT）是一种新兴的治疗实体器官疾病的方法。我们在宾夕法尼亚大学的小组已经进行了大量的研究，证明了间质性PDT治疗前列腺癌的可行性。我们的临床前和临床经验在此详细说明。研究设计/材料和方法：我们在临床前研究中治疗了16只犬，在I期研究中治疗了16名人类受试者，使用motexafin黄体介导的PDT治疗复发性前列腺腺癌。对这些患者进行光通量、药物水平和氧分布剂量测定。结果：我们证明了PDT治疗前列腺癌的安全性和综合性。然而，剂量分布和随后的整个前列腺组织坏死存在显著的可变性。结论：PDT是治疗前列腺癌的一种有吸引力的选择。然而，观察到的PDT剂量分布的变化转化为不确定的治疗再现性。我们未来的重点将是开发一种集成系统，能够实时检测和补偿剂量变化，以提供一致的整体PDT剂量分布。
Background and Objectives: Interstitial photodynamic therapy (PDT) is an emerging modality for the treatment of solid organ disease. Our group at the University of Pennsylvania has performed extensive studies that demonstrate the feasibility of interstitial PDT for prostate cancer. Our preclinical and clinical experience is herein detailed.Study Design/Materials and Methods: We have treated 16 canines in preclinical studies, and 16 human subjects in a Phase I study, using motexafin lutetium-mediated PDT for recurrent prostate adenocarcinoma. Dosimetry of light fluence, drug level and oxygen distribution for these patients were performed.Results: We demonstrate the safe and comprehensive treatment of the prostate using PDT. However, there is significant variability in the dose distribution and the subsequent tissue necrosis throughout the prostate.Conclusions: PDT is an attractive option for the treatment of prostate adenocarcinoma. However, the observed variation in PDT dose distribution translates into uncertain therapeutic reproducibility. Our future focus will be on the development of an integrated system that is able to both detect and compensate for dose variations in real-time, in order to deliver a consistent overall PDT dose distribution.